振东制药董事长李昆：中医药企业国际化首先要做好质量和科研

Core Viewpoint - The internationalization of traditional Chinese medicine (TCM) faces significant challenges, including the lack of unified international standards, difficulties in dialogue between Chinese and Western medicine, and insufficient clinical efficacy evidence. The company emphasizes quality and research as primary strategies for international expansion, followed by market considerations [1][3]. Group 1: Quality Assurance - The quality of medicinal materials is crucial as it directly affects the efficacy of drugs. Various factors influence the quality, including the geographical origin of the materials, harvesting seasons, processing methods, and storage techniques [3]. - The company has been exploring traceability in medicinal materials to ensure product quality over the years [3]. Group 2: Research and Evidence - The company aims to strengthen the acceptance of TCM among overseas doctors by building a robust evidence chain through scientific research. This is essential for enhancing public recognition of TCM products [3]. - There is a need for collaborative research efforts to provide sufficient evidence for regulatory acceptance, which is vital for advancing internationalization [3]. Group 3: Market Expansion - The company is also exploring the export of TCM functional foods, aiming to expand beyond the Chinese community into larger markets, contingent on maintaining quality and research foundations [3]. - The internationalization process for TCM companies is lengthy and challenging, requiring multiple cycles of "going out, bringing in, and going out again" [4].